Overcoming Vulnerabilities For Stewards of Member Health Data
As cybercriminals target valuable health and personal data, cyberattacks are a growing threat for healthcare organizations and self-insured companies. In a feature article for The…
Carbon
Pfizer Will Charge $3.5M For Its First FDA-Approved Gene Therapy
Pfizer will offer a warranty program for its first FDA-approved gene therapy. The hemophilia B treatment will go for $3.5M, matching the price tag…
PTC Wins FDA Approval For First Brain-Delivered Gene Therapy Kebilidi
Kebilidi represents the 13th gene therapy to score an FDA nod, but it's the first gene therapy to be administered directly in the brain.
Rocket Pharmaceuticals Announces FDA Approval of KRESLADI™️
Rocket Pharmaceuticals Announces FDA Approval of KRESLADI™️ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I) Read Full Story
Sarepta Duchenne Gene Therapy Wins Broader Use From FDA
Despite mixed results in testing, agency officials determined Elevidys showed enough to warrant a label that includes all patients at least 4 years of…
Sequoia and IOA Re Announce Expansion Into Personal Accident Reinsurance
Conshohocken, PA, October 24, 2023 – Sequoia Reinsurance Services and IOA Re are pleased to announce a collaboration with Everest Reinsurance Company (“Everest”) and/or its affiliates to expand their…
Stop Loss Companies and Reinsurers Help Employers Tackle Key Challenges
The high cost of healthcare claims is just one of several market challenges facing self-insured employers today. The cost of preventable hospital-acquired conditions adds…
The Dangers, Cost of Weight Loss Drugs — How to Avoid a Life Sentence
Beyond being a major public health challenge, obesity carries extreme implications for employers and their teams. In fact, a recent report estimates obesity cost…
U.S. Allows Use of Gamida’s Therapy in Blood Cancer Treatment
The U.S. Food and Drug Administration said on Monday it had approved the use of Gamida Cell Ltd's (GMDA.O), opens new tab cell therapy for…
U.S. FDA Approves Bristol Myers Squibb’s Breyanzi
U.S. FDA Approves Bristol Myers Squibb’s Breyanzi ® as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Chronic…
